vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 23.7%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
ESPR vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $185.2M |
| Net Profit | — | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | 50.6% | 8.6% |
| Net Margin | — | 0.9% |
| Revenue YoY | 143.7% | 23.7% |
| Net Profit YoY | — | -88.5% |
| EPS (diluted) | $0.32 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $185.2M | ||
| Q3 25 | $87.3M | $169.1M | ||
| Q2 25 | $82.4M | $154.7M | ||
| Q1 25 | $65.0M | $125.2M | ||
| Q4 24 | $69.1M | $149.7M | ||
| Q3 24 | $51.6M | $141.5M | ||
| Q2 24 | $73.8M | $126.7M | ||
| Q1 24 | $137.7M | $110.4M |
| Q4 25 | — | $1.7M | ||
| Q3 25 | $-31.3M | $17.3M | ||
| Q2 25 | $-12.7M | $-24.4M | ||
| Q1 25 | $-40.5M | $-21.7M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | $-29.5M | $-6.7M | ||
| Q2 24 | $-61.9M | $-15.7M | ||
| Q1 24 | $61.0M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | 50.6% | 8.6% | ||
| Q3 25 | -11.4% | 20.3% | ||
| Q2 25 | 8.6% | -6.1% | ||
| Q1 25 | -34.0% | -6.3% | ||
| Q4 24 | -6.4% | 10.7% | ||
| Q3 24 | -31.0% | 15.3% | ||
| Q2 24 | 3.5% | 11.8% | ||
| Q1 24 | 52.5% | -25.1% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | -35.9% | 10.2% | ||
| Q2 25 | -15.4% | -15.8% | ||
| Q1 25 | -62.2% | -17.3% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | -57.2% | -4.8% | ||
| Q2 24 | -83.9% | -12.4% | ||
| Q1 24 | 44.3% | -43.9% |
| Q4 25 | $0.32 | $0.00 | ||
| Q3 25 | $-0.16 | $0.06 | ||
| Q2 25 | $-0.06 | $-0.08 | ||
| Q1 25 | $-0.21 | $-0.07 | ||
| Q4 24 | $-0.14 | $0.05 | ||
| Q3 24 | $-0.15 | $-0.02 | ||
| Q2 24 | $-0.33 | $-0.05 | ||
| Q1 24 | $0.34 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $-302.0M | $274.2M |
| Total Assets | $465.9M | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $293.5M | ||
| Q3 25 | $92.4M | $263.8M | ||
| Q2 25 | $86.1M | $231.0M | ||
| Q1 25 | $114.6M | $250.6M | ||
| Q4 24 | $144.8M | $249.9M | ||
| Q3 24 | $144.7M | $249.8M | ||
| Q2 24 | $189.3M | $260.1M | ||
| Q1 24 | $226.6M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $-302.0M | $274.2M | ||
| Q3 25 | $-451.4M | $230.4M | ||
| Q2 25 | $-433.5M | $204.3M | ||
| Q1 25 | $-426.2M | $193.6M | ||
| Q4 24 | $-388.7M | $194.0M | ||
| Q3 24 | $-370.2M | $178.8M | ||
| Q2 24 | $-344.2M | $132.5M | ||
| Q1 24 | $-294.3M | $130.7M |
| Q4 25 | $465.9M | $949.9M | ||
| Q3 25 | $364.0M | $868.8M | ||
| Q2 25 | $347.1M | $815.3M | ||
| Q1 25 | $324.0M | $789.8M | ||
| Q4 24 | $343.8M | $785.0M | ||
| Q3 24 | $314.1M | $786.6M | ||
| Q2 24 | $352.3M | $749.5M | ||
| Q1 24 | $373.1M | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $16.3M | ||
| Q3 25 | $-4.3M | $35.7M | ||
| Q2 25 | $-31.4M | $-26.5M | ||
| Q1 25 | $-22.6M | $7.8M | ||
| Q4 24 | $-35.0M | $-3.9M | ||
| Q3 24 | $-35.3M | $-23.0M | ||
| Q2 24 | $-7.2M | $22.7M | ||
| Q1 24 | $53.8M | $-29.7M |
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $35.3M | ||
| Q2 25 | — | $-28.9M | ||
| Q1 25 | — | $7.5M | ||
| Q4 24 | — | $-4.2M | ||
| Q3 24 | $-35.5M | $-23.3M | ||
| Q2 24 | $-7.3M | $21.6M | ||
| Q1 24 | $53.8M | $-31.5M |
| Q4 25 | — | 8.6% | ||
| Q3 25 | — | 20.9% | ||
| Q2 25 | — | -18.7% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | -68.7% | -16.5% | ||
| Q2 24 | -9.9% | 17.0% | ||
| Q1 24 | 39.0% | -28.5% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.1% | 0.9% | ||
| Q1 24 | 0.1% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
